XT
MRKR icon

XTX Topco’s Marker Therapeutics MRKR Stock Holding History

XTX Topco’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.7K Sell
45,357
-18,210
-29% -$26.5K ﹤0.01% 3640
2026
Q1 		$82.6K Buy
63,567
+5,526
+10% +$8.77K ﹤0.01% 3160
2025
Q4 		$86.5K Buy
58,041
+36,269
+167% +$41.1K ﹤0.01% 2675
2025
Q3 		$19.4K Buy
+21,772
New +$26.9K ﹤0.01% 2336
2021
Q3 		– Sell
-2,417
Closed -$67K – 926
2021
Q2 		$67K Buy
+2,417
New +$63.6K 0.02% 703

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

XTX Topco's MRKR Position: Q2 2026 in Review

XTX Topco reduced its Marker Therapeutics (MRKR) stake by 29% in Q2 2026, selling an estimated $26.5K and leaving 45,357 shares worth $66.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3640.

XTX Topco first reported a position in MRKR in Q2 2021 and has held it in 5 quarters since. The position peaked at $86.5K in Q4 2025. 35 funds tracked by Wall St. Rank hold MRKR as of Q2 2026.

  • XTX Topco held 45,357 shares of Marker Therapeutics worth $66.7K as of Q2 2026.
  • XTX Topco sold 18,210 Marker Therapeutics shares in Q2 2026, an estimated $26.5K.
  • Marker Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3640 holding.
  • XTX Topco first reported a position in Marker Therapeutics in Q2 2021 and has held it in 5 quarters since.
  • XTX Topco's Marker Therapeutics position peaked at $86.5K in Q4 2025.
  • 35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.